S
Serena Merante
Researcher at University of Pavia
Publications - 63
Citations - 1602
Serena Merante is an academic researcher from University of Pavia. The author has contributed to research in topics: Imatinib mesylate & Systemic mastocytosis. The author has an hindex of 21, co-authored 62 publications receiving 1423 citations. Previous affiliations of Serena Merante include University of Naples Federico II & James Cook University Hospital.
Papers
More filters
Journal ArticleDOI
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study
Michele Baccarani,Daniela Cilloni,Michela Rondoni,Emanuela Ottaviani,Francesca Messa,Serena Merante,Mario Tiribelli,Francesco Buccisano,Nicoletta Testoni,Enrico Gottardi,Antonio De Vivo,Emilia Giugliano,Ilaria Iacobucci,Stefania Paolini,Simona Soverini,Gianantonio Rosti,Francesca Rancati,Cinzia Astolfi,Fabrizio Pane,Giuseppe Saglio,Giovanni Martinelli +20 more
TL;DR: All patients meeting the criteria for idiopathic or primary HES should be screened for the FIP1L1-PDGFRα rearrangement, and chronic imatinib treatment at doses as low as 100 mg daily ensures complete and durable responses.
Journal ArticleDOI
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
Simona Soverini,Alessandra Gnani,Sabrina Colarossi,Fausto Castagnetti,Elisabetta Abruzzese,Stefania Paolini,Serena Merante,Ester Orlandi,Silvia De Matteis,Antonella Gozzini,Ilaria Iacobucci,Francesca Palandri,Gabriele Gugliotta,Cristina Papayannidis,Angela Poerio,Marilina Amabile,Daniela Cilloni,Gianantonio Rosti,Michele Baccarani,Giovanni Martinelli +19 more
TL;DR: It is found that 83% of cases of relapse after an initial response are associated with emergence of newly acquired mutations and the spectra of mutants conferring resistance to dasatinib or nilotinib are small and nonoverlapping, except for T315I.
Journal ArticleDOI
Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation
TL;DR: 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued and two patients relapsed after 7 and 10 months and promptly responded after restarting therapy.
Journal ArticleDOI
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
Ilaria Iacobucci,Giuseppe Saglio,Gianantonio Rosti,Nicoletta Testoni,Fabrizio Pane,Marilina Amabile,Angela Poerio,Simona Soverini,Simona Bassi,Daniela Cilloni,Renato Bassan,Massimo Breccia,Francesco Lauria,Barbara Izzo,Serena Merante,Francesco Frassoni,Stefania Paolini,Enrico Montefusco,Michele Baccarani,Giovanni Martinelli +19 more
TL;DR: It is shown not only that achieving a major molecular remission at 12 months is predictive of a durable cytogenetic remission but also that patients who achieved a major Molecular remission already at the time of first achieving a CCgR have significantly longer cytogenetics remission durations than those without this magnitude of molecular response.
Journal ArticleDOI
Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.
Francesco Passamonti,Ercole Brusamolino,Mario Lazzarino,Claudia Baratè,Catherine Klersy,Ester Orlandi,A. Canevari,G. Castelli,Serena Merante,Carlo Bernasconi +9 more
TL;DR: This study demonstrates in a large series of patients, observed for a long period, that pipobroman is effective in the long-term control of PV.